ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Meta-analysis adds evidence to association between omega-3 supplementation and lower heart rate

Friendly User's Guide for the Timing of Nutritional Supplements

The Health Benefits of Manuka Honey

Increase Your Magnesium Intake

Vitamin D supplementation could ease IBS symptoms

Top Tips to Boost Your Immunity

11 Amazing Health Benefits of Using Baking Soda

Nicotinamide riboside shows promise for treatment of Alzheimer’s disease

Exercise, calcium, vitamin D, and other factors linked with fewer injurious falls

Mediterranean diet associated with lower risk of aggressive prostate cancer

 
Print Page
Email Article

J&J Changes Remicade Label To Show Lymphoma Risk

  [ 141 votes ]   [ Discuss This Article ]
www.ProHealth.com • October 8, 2004


By Hollister H. Hovey Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--

Johnson & Johnson's (JNJ) Centocor unit sent physicians a letter Thursday warning them the incidence of a blood cancer called lymphoma appears to be higher in patients who received its drug Remicade than in the normal population. Remicade belongs to a class of drugs known as anti-tumor necrosis factor, or TNF, agents that also include Amgen Inc. (AMGN) and Wyeth's (WYE) Enbrel and Abbott Laboratories' (ABT) Humira.

It is difficult to know whether or how much this class of drugs contribute to this increase in malignancies because rheumatoid arthritis and Crohn's disease are themselves associated with an increased risk of lymphoma, Centocor said. Enbrel and Humira already have similar warnings on their labels. The potential role of these drugs in the development of malignancies is not known, the new label says.

Centocor is changing the label on Remicade to reflect the warnings. The Remicade label had mentioned a higher rate of lymphoma previously, but the language was more vague. In the letter, Centocor said that the incidence in rheumatoid arthritis clinical trials was about threefold higher than for the general population. Among all completed trials, this incidence was about sixfold higher.

Centocor spokesman Michael Parks stressed that these trials are comparing the drug to the general population - not to the higher-risk patient groups that Remicade treats. "No studies have been conducted that include patients with a history of malignancy or that continue treatment in patients who develop malignancy while receiving Remicade; thus, caution should be exercised in considering Remicade treatment of these patients," the new label reads.

Despite that and the fact that the absolute number of lymphoma cases in clinical trials was low, Centocor felt "it is important that physicians have this information to make an informed decision while we continue to follow this issue to help better characterize the potential risk of lymphoma in the future," the company said in an accompanying statement.

On Aug. 11, Centocor warned of serious and sometime fatal side effects for people taking Remicade. The company said serious blood-related disorders including leukopenia and neutropenia have occurred and that some patients have died. The company also warned of rare cases of a neurologic disorder known as systematic vasculitis. Labels for Remicade had already warned of blood disorders and neurologic events.

Remicade was approved by the FDA in 1998. Since then, 509,000 patients have been treated with the drug worldwide. Up to 1 million Americans suffer from Crohn's disease, an inflammation of the digestive track, while more than 2 million Americans suffer from rheumatoid arthritis, or inflamed joints.

-By Hollister H. Hovey, Dow Jones Newswires Dow Jones Newswires Copyright (C) 2004 Dow Jones & Company, Inc. All Rights Reserved



Post a Comment

Featured Products From the ProHealth Store
Ultra EPA  - Fish Oil Vitamin D3 Extreme™ Optimized Curcumin Longvida®


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get Energized with Malic Acid & Magnesium
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Dreaming of a Good Night's Sleep? Dreaming of a Good Night's Sleep?
Improve Cardiovascular and Metabolic Health with Omega-7 Improve Cardiovascular and Metabolic Health with Omega-7
Priming Your Immune System for Cold & Flu Season Priming Your Immune System for Cold & Flu Season
Herbal Inflammation Management for Whole Body Health Herbal Inflammation Management for Whole Body Health
Guarding Against the Dangers of Vitamin D Deficiency Guarding Against the Dangers of Vitamin D Deficiency

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2018 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map